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RIASSUNTO 
Presupposti dello studio: La prognosi del cancro gastrico non è migliorata in maniera 
significativa negli ultimi anni. Attualmente i due principali fattori prognostici sono rappresentati 
dallo stadio TNM alla diagnosi e dalla possibilità di ottenere un intervento chirurgico 
apparentemente radicale. 
Scopo dello studio: Individuare nuovi fattori prognostici indipendenti che permettano di 
migliorare la stratificazione del rischio di decesso per carcinoma gastrico e selezionare quei 
soggetti che potrebbero beneficiare di una terapia adiuvante dal momento che la stadiazione TNM 
presenta un certo grado di incertezza soprattutto negli stadi intermedi e che, nonostante una 
chirurgia apparentemente radicale, la prognosi rimane insoddisfacente in una significativa 
percentuale di casi. Si è studiato il microambiente tumorale per le crescenti evidenze indicanti un 
ruolo fondamentale del microambiente tumorale nei processi di proliferazione, angiogenesi e 
metastatizzazione. 
Materiali e metodi: Sono stati arruolati 333 soggetti sottoposti ad intervento chirurgico per 
carcinoma gastrico (stadi I- IV) a partire dal 1991. Ogni soggetto è stato sottoposto ad un prelievo 
di sangue venoso periferico nel pre-operatorio dalle cui PBMC è stato estratto il DNA (germline) 
per la discriminazione allelica. Lo studio ha esaminato un set di polimorfismi di tre diversi geni 
(codificanti per le citochine CXCL12 e IL8 e per il recettore CXCR4) e la presente tesi riporta dei 
risultati parziali che riguardano i seguenti tre polimorfismi: rs1801157, rs2228014 e rs4073. 
Risultati: L’analisi di sopravvivenza non ha riportato risultati statisticamente significativi (p-
value>0,05) nei modelli genetici allelico, dominante e recessivo. Per quanto riguarda i dati 
anatomo-patologici esaminati non è stata individuata una correlazione statisticamente significativa 
(p-value>0,05) tra i polimorfismi e grading, infiltrazione linfatica e venosa nei tre modelli 
genetici. È stata, invece, evidenziata un’associazione debolmente significativa (p-value=0,049) tra 
i genotipi A/A e A/T del polimorfismo rs4073 del gene codificante per IL8 e il coinvolgimento 
linfonodale nel modello dominante. Alla regressione logistica con variabile dipendente il 
coinvolgimento linfonodale: odds ratio=0,602, p-value=0,050, I.C.95%=0,363-0.999. All’analisi 
multivariata il polimorfismo non è risultato essere un fattore indipendente dal parametro T della 
stadiazione TNM (odds ratio=0,663; I.C. 95%=0,361-1,215; p-value:0,184). 
Conclusioni: Questo lavoro suggerisce che vi siano delle evidenze interessanti a favore 
dell’associazione dell’allele T del polimorfismo rs4073 e la riduzione del rischio di metastasi 
linfonodali, ma che non possano essere ritenute conclusive. Sono pertanto necessari ulteriori studi 
allo scopo di analizzare ulteriori polimorfismi del gene per IL8 che potrebbero spiegare, con un 
livello di significatività più consistente, l’associazione tra la proteina e il coinvolgimento 
linfonodale. 
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SUMMARY 
Background: In the last few years gastric cancer’s prognosis hasn’t improved. At the present the 
two main prognostic factors are the TNM staging classification and surgery with radical intent. 
Objective: To identify independent prognostic factors to improve the risk stratification of gastric 
cancer’s death and to select patients at high risk to be submitted to adjuvant treatment because the 
TNM classification presents uncertainty primarily in the intermediate stages and, although an 
apparently radical surgery, gastric cancer prognosis remains poor. The study is based on tumor 
microenvironment because the are many recent evidences that underline its fundamental role in 
tumor growth, angiogenesis and metastasis. 
Materials and Methods: 333 patients affected with gastric cancer at different TNM stages (I- IV) 
of disease who underwent radical surgery from 1991. Before surgery a sample of peripheral blood 
was withdrawn from each patient. From each sample PBMC were used for DNA (germline) 
isolation for allelic discrimination assay. This study evaluated a set of polymorphisms of three 
different genes coding for CXCL12 and IL8 (cytokines) and CXCR4 (receptor) and the present 
work shows the partial results concerning the following three polymorphisms: rs1801157, 
rs2228014 e rs4073. 
Results: Survival analysis reported no statistically significant results (p-value>0,05) in allelic, 
dominant and recessive genetic models. As regards the data anatomo-pathological, a statistically 
significant correlation between polymorphisms and grading and lymphatic and venous infiltration 
in the three genetic models was not found (p-value>0,05). Instead, a weakly association (p-
value=0,049) between genotypes A/A and A/T of rs4073 of the gene encoding for IL8 and lymph 
node involvement was found in the dominant model. At the logistic regression with lymph node 
involvement as dependent variable: odds ratio=0,602, p-value=0,050, I.C.95%=0,363-0.999. At 
the multivariate analysis the polymorphism wasn’t found to be an independent factor of T 
parameter of TNM staging (odds ratio=0,663; I.C. 95%=0,361-1,215; p-value:0,184). 
Conclusions: The results of this thesis suggest that there are interesting evidences in favour of the 
association between the allele T of rs4073 and the decreased risk of lymph node metastasis but 
that these can’t be considered conclusive. New studies are needed to analyze additional 
polymorphisms of the gene encoding for IL8 because these can explain the association between 
the protein and the lymph node involvement with a more consistent level of significance. 
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1. INTRODUCTION 
1.1 Epidemiology 
Despite a major decline in incidence and mortality over several decades, stomach cancer 
is still the fourth most common cancer and the second most common cause of cancer 
death in the world. There is a 10-fold variation in incidence between populations at the 
highest and lowest risk. The global distribution of gastric cancer varies substantially 
across geographical regions which illustrate the multitude of factors that are associated 
with the incidence, survival and mortality of the disease [1,2]. The Asian countries 
account for the majority of the world's cases while Europe and the Americas combined 
makeup less than a quarter of the world disease burden. Seventy-three percent of gastric 
cancer cases are diagnosed in Asia; almost 50% of the world's cases are diagnosed in 
China alone. Europe accounts for an additional 15% and Central and South America 
contribute 7% of the global burden [3,4]. Within these global regions, there is further 
variability as to which populations are more greatly affected. The incidence rate in men is 
double that of women and incidence increases with age with a peak incidence between the 
fifth and the seventh decades. Even within the same geographic region certain ethnic 
groups have significantly higher risk of disease. Within the United States, Hispanics, 
African Americans, and Native Americans are more frequently affected than Caucasian 
Americans [3]. However, ethnic predisposition cannot be considered alone since 
socioeconomic status also impacts disease incidence. In the last decades a decline in 
incidence was observed and probably due to improved nutrition, food preservation (great 
intake of fresh fruits and vegetables), better prevention, earlier diagnosis and treatment. 
Although the disease still carries a poor prognosis.  
In Italy we register a high variability in incidence rate and mortality for gastric cancer 
with a maximum in Toscana, Emilia Romagna, Friuli and Marche, and a minimum in 
Campania e Puglia [5]. 
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1.2 Histologic classification
 
Several classification systems exist to define gastric cancer but the most frequently used 
is the Lauren classification. The Lauren classification defines two main histologic 
subtypes: Intestinal type and diffuse type, plus indeterminate type as uncommon variant 
[6]. Each subtype represents distinct clinical and epidemiologic characteristics. There are 
rare cases of gastric carcinomas that display features of both histologic subtypes. The 
morphologic differences between the two subtypes are related to intercellular adhesion 
molecules, which are preserved in intestinal type disease and defective in diffuse gastric 
carcinoma. The relative frequencies are approximately 54% for intestinal type, 32% for 
the diffuse type, and 15% for the indeterminate type [7]. There are indications that the 
diffuse type gastric carcinoma is more often seen in female and young individuals [8,9], 
while the intestinal type adenocarcinoma is more often associated with intestinal 
metaplasia and Helicobacter pylori infection [10,11]. 
The 2010 WHO classification recognizes four major histologic patterns of gastric 
cancers: tubular, papillary, mucinous and poorly cohesive (including signet ring cell 
carcinoma), plus uncommon histologic variants [12]. The classification is based on the 
predominant histologic pattern of the carcinoma which often co-exists with less dominant 
elements of other histologic patterns. Tubular adenocarcinoma is the most common 
histologic type of early gastric carcinoma. It tends to form polypoid or fungating masses 
grossly, and histologically demonstrates irregularly distended, fused or branching tubules 
of various sizes, often with intraluminal mucus, nuclear and inflammatory debris. 
Papillary adenocarcinoma is another common histologic variant often seen in early gastric 
carcinoma. It tends to affect older people, occur in the proximal stomach, and is 
frequently associated with liver metastasis and a higher rate of lymph node involvement. 
Histologically, it is characterized by epithelial projections scaffolded by a central 
fibrovascular core. Mucinous adenocarcinoma accounts for 10% of gastric carcinoma. 
Histologically it is characterized by extracellular mucinous pools which constitute at least 
50% of tumor volume. The tumor cells can form glandular architecture and irregular cell 
clusters, with occasional scattered signet ring cells floating in the mucinous pools. Signet 
ring cell carcinoma and other poorly cohesive carcinomas are often composed of a 
mixture of signet ring cells and non-signet ring cells. Poorly cohesive non-signet ring 
tumor cells are those that morphologically resemble histiocytes, lymphocytes, and plasma 
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cells. Those tumor cells can form irregular microtrebaculae or lace-like abortive glands, 
often accompanied by marked desmoplasia in the gastric wall and with a grossly 
depressed or ulcerated surface. When it occurs at the antropyloric region with serosal 
involvement, the carcinoma tends to have lymphovascular invasion and lymph node 
metastasis. Because signet ring cell and other poorly cohesive carcinomas at antroplyoric 
region have a propensity to invade duodenum via submucosal and subserosal routes 
including subserosal and submucosal lymphatic spaces, special attention needs to be paid 
to those routes when a distal margin frozen section is requested at the time of surgical 
resection. Special stains such as cytokeratin immunohistochemistry can help detect 
morphologically occult signet ring cells in the lamina propria. One important differential 
diagnosis of neoplastic signet ring cells in gastric mucosa is benign pseudo-signet ring 
cells which can remarkably mimic signet ring cell carcinoma. Those pseudo-signet ring 
cells sometimes can demonstrate cytological atypia, even with mitoses. However, those 
pseudo-signet ring cells do not reveal invasive pattern with reticulin stain which 
highlights pseudo-signet ring cells confined within basement membrane with intact acinar 
architecture [13]. In addition to the above four major histologic subtypes, WHO 
classification also endorses other uncommon histologic variants, such as adenosquamous 
carcinoma, squamous carcinoma, hepatoid adenocarcinoma, carcinoma with lymphoid 
stroma, choriocarcinoma, parietal cell carcinoma, malignant rhabdoid tumor, 
mucoepidermoid carcinoma, paneth cell carcinoma, undifferentiated carcinoma, mixed 
adeno-neuroendocrine carcinoma, endodermal sinus tumor, embryonal carcinoma, pure 
gastric yolk sac tumor and oncocytic adenocarcinoma, all listed in Table 1, with Lauren’s 
classification for comparison. Gastric carcinoma with lymphoid stroma (medullary 
carcinoma) is one of the uncommon subtypes. It occurs more commonly in proximal 
stomach and generally follows a less aggressive clinical course. Micropapillary 
carcinoma of stomach is a newly recognized histologic variant characterized by small 
papillary clusters of tumor cells without a distinct fibrovascular core. Micropapillary 
carcinoma of stomach, as its counterpart at other organs, tends to form endolymphatic 
tumor emboli and metastasize to lymph nodes.  
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1.3 Classification based on anatomic location 
For the classification based on anatomic location, difficulty often arises when the tumor is 
located at proximal stomach or cardia, especially when the tumor also involves 
gastroesophageal junction (GEJ). It is not only because there are shared histologic 
features and immunophenotypes between the inflamed gastric cardiac mucosa due to 
Helicobacter infection and the metaplastic columnar epithelium-lined distal esophageal 
mucosa secondary to reflux disease, but also because there is no universal consensus 
regarding the anatomic definition of gastric cardia [14,15]. Several classifications were 
proposed in order to address this issue. The scheme endorsed by the International Gastric 
Cancer Association separates gastric cancers into type I, type II and type III, to represent 
the tumors at distal esophagus, at cardia and at the stomach distal to cardia, respectively 
[16]. This classification, however, has not clearly defined the criteria for each of these 
anatomic locations. Most recently, the 7th Edition of the TNM classification by American 
Joint Committee on Cancer (AJCC) has simplified the classification of the carcinoma at 
proximal stomach based on the location of tumor epicenter and the presence or absence of 
GEJ involvement [17]. The tumor is to be stage grouped as esophageal carcinoma if its 
epicenter is in the lower thoracic esophagus or GEJ, or within the proximal 5 cm of 
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stomach (i.e., cardia) with the tumor mass extending into GEJ or distal esophagus. If the 
epicenter is >5 cm distal to the GEJ, or within 5 cm of GEJ but does not extend into GEJ 
or esophagus, it is stage grouped as gastric carcinoma [17]. This classification, although 
easy for pathologists to follow, could still face some challenges. For example, a bulky 
gastric cardiac cancer with its epicenter 4 cm below GEJ will still be diagnosed and 
classified as an esophageal tumor if the proximal end of tumor extends into GEJ by only 
0.5 cm (even if the distal end of tumor is 4 cm from the epicenter extending into the 
stomach). For the operating surgeon who sees the tumor in situ, it may be difficult for him 
or her to accept this tumor as an esophageal cancer. In addition, a recent retrospective 
study by Huang et al. shows that cardiac carcinoma involving GEJ or distal esophagus is 
more appropriately classified and staged as gastric rather than esophageal cancers, at least 
in the Chinese population [18]. In that study, cardiac carcinomas were staged according to 
the depth of invasion, status of positive lymph nodes and distant metastasis, as both 
gastric and esophageal tumors. When the tumor stage is studied and compared with 
cumulative survival, the findings support that it is more appropriately to group and stage 
cardiac cancers as stomach in origin [18]. To better separate gastric cardiac carcinoma 
from esophageal or GEJ malignancy, more studies are apparently needed, such as a larger 
patient sample, molecular profiling of the tumor, clinical follow up data, and defining the 
tumor location after neoadjuvant therapy as to determine whether the initially bulky 
tumor was more “gastric” or more “GEJ/esophagus” in origin. 
 
1.4 Early and advanced gastric carcinoma 
Early gastric carcinoma is defined as invasive carcinoma confined to mucosa and/or 
submucosa, with or without lymph node metastases, irrespective of the tumor size [19]. 
Most early gastric carcinomas are small, measuring 2 to 5 cm in size, and often located at 
lesser curvature around angularis. Some early gastric carcinoma can be multifocal, often 
indicative of a worse prognosis. Grossly, early gastric carcinoma is divided into Type I 
for the tumor with protruding growth, Type II with superficial growth, Type III with 
excavating growth, and Type IV for infiltrating growth with lateral spreading. Type II 
tumor is further divided to IIa (elevated), IIb (flat) and IIc (depressed), as proposed by the 
Japanese Endoscopic Society [20]. A more recent Paris classification has endorsed three 
gross patterns for superficial neoplastic lesions in gastrointestinal tract. Grossly and 
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endoscopically, the tumor is classified as Type 0-I for polypoid growth (which is 
subcategorized to 0-Ip for pedunculated growth and 0-Is for sessile growth), Type 0-II for 
nonpolypoid growth (which is subcategorized into Type 0-IIa for slightly elevated 
growth, Type 0-IIb for flat growth, and Type 0-IIc for slightly depressed growth), and 
Type 0-III for excavated growth [21]. Histologically, the most common forms of early 
gastric carcinoma are well differentiated, mostly with tubular and papillary architecture. 
The distinction between well-differentiated carcinoma and high grade dysplasia or 
carcinoma in situ can be challenging when only mucosal tissue is available for histologic 
assessment. Intramucosal invasion may not be as easily confirmed as an invasive 
carcinoma into submucosa where stromal desmoplasia is usually evident. The distinction 
between intramucosal carcinoma and carcinoma in situ or high grade dysplasia is 
important, as the intramucosal carcinoma of stomach, unlike the intramucosal carcinoma 
in the colon, does metastasize. Generally, the useful histologic features of intramucosal 
invasion are single tumor cells in the lamina propria and significantly fused neoplastic 
glands of various sizes. The prognosis of early gastric carcinoma is excellent, with a 5 
years survival rate as high as 90% [22]. In contrast, the advanced gastric carcinoma which 
invades into muscularispropria or beyond carries a much worse prognosis, with a 5 years 
survival rate at about 60% or less [23]. The gross appearance of advanced gastric 
carcinomas can be exophytic, ulcerated, infiltrative or combined. Based on Borrmann’s 
classification, the gross appearance of advanced gastric carcinomas can be divided into 
type I for polypoid growth, type II for fungating growth, type III for ulcerating growth, 
and type IV for diffusely infiltrating growth which is also referred to as linitisplastica in 
signet ring cell carcinoma when most of gastric wall is involved by infiltrating tumor 
cells. Histologically, advanced gastric carcinoma often demonstrates marked architectural 
and cytological heterogeneity, with several co-existing histologic growth patterns. The 
distinction between early and advanced gastric carcinoma before resection is clinically 
important because it helps decide if a neoadjuvant (pre-operative) therapy which has 
shown to improve disease free survival and overall survival [24,25] is warranted. While 
the macroscopic appearance is informative, the most accurate pre-operative staging 
information is generally obtained with endoscopic ultrasonography (EUS) and computer 
tomography (CT) [26]. 
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1.5 Risk factors for gastric cancer 
Risk factors for gastric cancer can be environmental and lifestyle related or genetic.  
Helicobacter pylori (H. pylori) is the primary environmental carcinogen as this ancient 
bacterium has a complex ability to interact with its human host. Smoking and salt are 
strong independent risk factors for gastric cancer whereas alcohol is only a risk when it is 
heavily consumed. Red meat and high fat increase the risk of gastric cancer however 
fresh fruits, vegetables (allium family) and certain micronutrients (selenium, vitamin C) 
reduce the risk, with evidence lacking for fish, coffee and tea. Foods that inhibit H. pylori 
viability, colonization and infection may reduce cancer risk. Obesity is increasingly 
recognized as a contributory factor in gastric cardia carcinogenesis. Therefore, modest 
daily physical activities can be protective against cancer. Foundry workers are at risk for 
developing gastric cancer with dust iron being an important cause. Other risk factors 
include Epstein-Barr virus (EBV), possibly JC virus and radiation but the effects of these 
are likely to remain small [27]. 
Early studies revealed that gastric cancer was less common in patients with blood group 
0, but was frequently associated with blood group A which increases the risk by 16-20%. 
A positive family history of gastric cancer has been associated with an increased (~three-
fold) risk of gastric cancer. Interestingly, subjects with both a positive family history and 
infection with cagA-positive H. pylori strains had a 16-fold increased risk of non-cardia 
gastric cancer. Polymorphisms in a wide variety of genes, present in a significant 
proportion of the normal population, may affect the activity of key inflammatory 
molecules and modify the effect of environmental exposures. Thus, gene-environmental 
interactions could explain the high inter- individual and/or geographic variations in the 
gastric cancer incidence. A variety of associations between  gastric cancer risk, H. Pylori 
infection, and specific HLA alleles have been described. 
 
1.6 Precancerous lesions 
The secondary prevention focuses on patients at risk of developing gastric cancer. Gastric 
atrophy, indeed, is considered the first relevant step in the histogenesis of intestinal type 
gastric cancer according to the multistep process suggested by Correa [28]. In fact, the 
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risk of gastric cancer is closely related to the grade and extension of gastric atrophy being 
up to 80-90 folds higher in respect to the general population in patients with severe 
atrophy involving both antrum and body. Gastric atrophy assumes a precancerous 
meaning particularly when it is located or extended in the corpus. This latter condition, 
indeed, damaging parietal cells decreases the acidity in the stomach and provokes the 
transformation of nitrates food components in nitrites and nitrosamides which are critical 
for the onset of the gastric carcinogenic process. This hypothesis links the theory of “N-
nitroso compounds-mediated gastric cancer risk” with that of “H. pylori-related gastric 
cancer risk” suggesting an  “integrated model” of gastric carcinogenesis. Chronic atrophic 
gastritis is often associated with intestinal metaplasia, the subsequent step in the Correa 
model of H. pylori-related gastric carcinogenesis. The prevalence of intestinal metaplasia 
was significantly higher in H. pylori-positive (43%) than in H. pylori-negative subjects 
(6.2%). Intestinal metaplasia has been classified according to Jass and Filipe as complete 
or type I, or incomplete which comprises types II and III. The association between the 
risk of gastric cancer development and intestinal metaplasia subtypes is, however, not 
universally accepted. Intestinal metaplasia involving the lesser curvature, from the cardia 
to the pylorus, or the entire stomach, was associated with a higher risk of gastric cancer 
than focal or antral predominant intestinal metaplasia. Thus, the distribution of intestinal 
metaplasia rather than intestinal metaplasia subtype may provide a higher predictive value 
of cancer risk [29].  
The next step in the cascade of morphological changes in gastric carcinogenesis is 
dysplasia that usually develops in the H. pylori infection, atrophy and intestinal 
metaplasia setting. The development and progression of dysplastic changes is clearly 
associated with H. pylori. This process includes a continuum of progressively 
dedifferentiated phenotypes which may result in a new cell. According to the definition of 
the World Health Organization, dysplasia is now called non-invasive gastric neoplasia, 
indicating a pre-invasive neoplastic change in the gastric glands. The higher the grade of 
dysplasia, the greater the risk of developing invasive gastric cancer. The majority of 
carcinoma found in follow-up studies and which were discovered within one year of the 
diagnosis of dysplasia may indicate that the carcinoma was already present at the time of 
diagnosis of dysplasia [29]. 
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1.7 Cancer microenvironment and angiogenesis 
Multiple genetic and epigenetic alterations in oncogenes, tumor suppressor genes, cell 
cycle regulators, cell adhesion molecules and DNA repair genes, as well as genetic 
instability and telomerase activation are responsible for tumorigenesis and progression of 
gastric cancer [30,31,31]. Differences exist in the pathways leading to intestinal and 
diffuse types of gastric carcinoma. Gastric cancer cells express a wide array of growth 
factors and cytokines that act via autocrine, paracrine and juxtacrine mechanisms in the 
tumor microenvironment [31,33]. These complex interactions between tumor cells and 
stromal cells confer morphogenesis, angiogenesis, invasion and metastasis. Again the 
expression of these mediators varies depending on the histological subtype. 
Angiogenesis is a complex process in which numerous stimulatory and inhibitory signals, 
such as integrins, angiopoietins, chemokines, oxygen sensors, growth factors, 
extracellular matrix proteins, and many other molecules are involved. The relationship 
between  the extracellular matrix influencing angiogenesis and the development or 
prognosis of gastric cancer is not yet well known (Figure 1) [34].  
 
 
 
Figure 1. Interaction between gastric cancer cells and stromal 
cells influences angiogenesis through various angiogenic factors 
and cytokines. EMT epithelial-to-mesenchymal transition; MSCs 
mesenchymal stem cells; EPCs endothelial progenitor cells. 
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Angiogenesis of tumor is mediated by various molecules released by tumor cells and 
tumor microenvironment [35,36] and gastric cancer cells produce various angiogenic 
factors, including VEGF [37], CXCL12 [38], IL-8 [39], FGF-2 [40], and platelet-derived 
endothelial cell growth factor (PD-ECGF) [41].  
The CXCL12-CXCR4 pathway has been reported to impact the progression of various 
malignancies by  regulating trafficking of normal and malignant cells [42]. CXCL12-
CXCR4 also indirectly promotes tumor metastasis by mediating proliferation and 
migration of tumor cells and enhancing tumor-associated angiogenesis. The activation of  
angiogenesis seems to be regulated by pro-inflammatory cytokines, tumor necrosis factor 
 (TNF) and interferon .  CXCL12 gene is located on chromosome 10q 11.1, and it has 
been revealed that a single nucleotide polymorphism (SNP), a guanine to adenine 
(G→A), at position 801 of the 3′-untranslated gene region may affect the expression of 
CXCL12/SDF1 chemokine [43]. The CXCL12/SDF1 A/A homozygotes had been 
suggested to alter the production of CXCL12/SDF1 and are associated with the risk of 
carcinogenesis of various origins. Moreover the angiogenic effect of  CXCL12 is partly 
mediated through an induction of  Vascular Endothelial Growth Factor (VEGF), 
suggesting an additive and synergistic mechanism to amplify angiogenesis [42,43,44]. 
CXCR4 is the chemokine receptor most commonly expressed in tumors and it is the 
receptor of CXCL12. CXCR4, is located on chromosome 2q2 and a silent SNP 
(rs2228014) of CXCR4, a cytosine to thymine (C→T), is found at codon 138 [42] and it 
has been demonstrated to be associated with stages III and IV and also lymph nodes 
metastasis of oral cancer [45]. The angiogenetic role of CXC12-CXCR4 pathway is 
confirmed by the neutralizing effect on angiogenesis of antibodies against either CXCL12 
or CXCR4 [44]. 
The first angiogenic chemokine to be described was CXCL8/IL8. IL8 was the first 
angiogenic chemokine described since 1992. This chemokine is a strong inducer of 
angiogenesis and also acts as a potent chemoattractant and activator of neutrophils and is 
closely related to the tumorigenesis, adhesion, invasion and metastasis of cancer. IL8 
have been shown to be angiogenic upon interaction with the appropriate chemokine 
receptors expressed on endothelial cells. Although endothelial cells are characterized by a 
large degree of heterogeneity dependent upon tissue types, species and vessel caliber, and 
it is therefore difficult to predict which effect IL8 will be dominant [46]. A well-
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characterized SNP at the -251 T/A (rs4073) position of the IL-8 gene has been studied to 
determine its involvement in several pathologies, including gastric cancer [47,48]. 
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2. WORKING HYPOTHESIS 
Early stage gastric cancer, even if surgically curable, maintains a small prevalence of 
tumor recurrence and, finally, death. For this subgroup, there are increasing bodies of 
evidence that the best risk stratification for cancer recurrence comes from TNM 
classification associated with specific molecular prognostic factors. Recent studies have 
shown that interactions between tumor and stromal cells create a unique 
microenvironment, essential for tumor growth and metastasis. Chemokines affect tumor 
development indirectly by influencing angiogenesis, tumor leukocyte interactions, as well 
as directly by influencing tumor transformation, survival and growth, invasion and 
metastasis.  
Our working hypothesis started from the interesting role of the genetic polymorphisms of 
CXCR4 and CXCL12 axis and IL8 on the prognosis of various types of solid tumors, and 
from the lack of the literature on their association with gastric cancer.  
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3. MATHERIALS AND METHODS 
From the large biobank of Clinica Chirurgica I (University of Padova, Italy) 333 patients 
affected with gastric cancer at different TNM stages of disease (I- IV) who underwent 
radical surgery since 1991 were selected. Before surgery, and after informed consent, a 
sample of peripheral blood was withdrawn from each patient and stored. From each 
sample PBMC (Peripheral Blood Mononuclear Cells) were used for DNA (germline) 
isolation for allelic discrimination assay.  
Variables object of study were: gender, age, overall survival (expressed in months), stage, 
TNM classification, lymphatic and venous invasion, grading, lymph node metastasis. This 
study evaluates a set of polymorphisms of three different genes coding for CXCL12 and 
IL8 (cytokines) and CXCR4 (receptor) and the partial results concerning the following 
three polymorphisms: rs1801157, rs2228014 e rs4073 (Table 2).  
 
GENE ID POLYMORPHISM ALLELIC VARINCES 
CXCL12 (SDF1) 
Homo sapiens 
chemokine (C-X-C 
motif) ligand 12, 
transcript variant 2, 
chromosome 10 
rs1801157  CXCL12-801GG 
CXCL12-801AA 
CXCL12-801G/A 
 
CXCR4 
Homo sapiens 
chemokine (C-X-C 
motif) receptor 4, 
chromosome 2 
rs2228014 CXCR4-138TT 
CXCR4-138CC 
CXCR4-138C/T 
IL-8  
chromosome 4 
rs4073 IL8-251AA 
IL8-251TT 
IL8-251A/T 
Table 2. Polymorphisms object of study 
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Genomic DNA was extracted by QIAamp DNA blood mini kits (Qiagen, Valencia, USA) 
according to the manufacture's instructions. DNA was dissolved in TE buffer [10 mM 
Tris (pH 7.8), 1 mM EDTA] and then quantitated by a measurement of OD260. Final 
preparation was stored at −20 °C and used as templates for PCR.  
The CXCL12-3′A and CXCR4 polymorphisms were determined by polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The sequences of 
primers used to amplify the CXCL12-3′A genotype were 5′-CAGTCAACCTGGGCAAA 
GCC-3′ and 5′-CCTGAGAGTCCTTTTGCGGG-3′, and those used for the amplification 
of CXCR4 genotype were 5′-AACTTCCTATGCAAGGCAGT-3′ and 5′-
TATCTGTCATCTGCCTCACT-3′. PCR was performed in a 10 μL reaction mixture 
containing 100 ng DNA template, 1.0 μL of 10× PCR buffer (Invitrogen, Carslbad, CA), 
0.25 U of Taq DNA polymerase (Invitrogen, Carslbad, CA), 0.2 mM dNTPs (Promega, 
Madison, WI), and 200 nM of each primer (MDBio, Taipei, Taiwan). The PCR cycling 
started at 94 °C for 5 min followed by 35 cycles of 94 °C for 1 min, 60 °C for 1 min, and 
72 °C for 2 min, with a final step at 72 °C for 20 min to allow a complete extension of all 
PCR fragments. PCR products of CXCL12 and CXCR4 gene were subjected to 
enzymatic digestion by incubation with HpaII and BccI for 4 h at 37 °C and then 
submitted to electrophoresis in 3% agarose gels. For CXCL121, wild type homozygous 
alleles (G/G) yielded 100 and 193-bp products, the heterozygous alleles (G/A) yielded 
100-, 193- and 293-bp products, while the mutated type homozygous alleles (A/A) 
yielded a 293-bp product. For CXCR4 gene, wild-type homozygous alleles (C/C) yielded 
103 and 133-bp products, the heterozygous alleles (C/T) yielded 103-, 133- and 236-bp 
products, while the mutated type homozygous alleles (T/T) yielded a 236-bp product. 
Digested RFLP products were electrophoresed in 2 % agarose gels, stained with ethidium 
bromide, visualized under ultraviolet light, and photodocumented. 
The IL8 polymorphisms were determined by PCR-RFLP assay. The sequences of primers 
used to amplify IL8 genotype were forward primer 5′-
CATGATAGCATCTGTAATTAACTG-3′ and reverse primer 5′-CTCATCTTT 
TCATTATGTCAGAG-3′. PCR conditions involved an initial denaturation step of 94 °C 
5 min, followed by 35 cycles of 94 °C for 45 s and 52 °C for 45 s. Then, another cycle of 
72 °C for 7 min was carried out before termination. Ten microliters of the PCR product 
was digested after incubation for 60 min at 37 °C with 0.5 U of the restriction enzyme 
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MfeI (New England BioLabs, Ipswich, MA, USA). To analyze the polymorphism, gel 
electrophoresis was performed on the digested PCR products; the AA homozygotes 
yielded bands of 202 bp and 147 bp, the TT wild type yielded one band of 349 bp, and the 
TA heterozygotes yielded three bands of 349 bp, 202 bp, and 147 bp. Digested RFLP 
products were electrophoresed in 2 % agarose gels, stained with ethidium bromide, 
visualized under ultraviolet light, and photodocumented. 
Statistical analysis was performed with STATA 11.2 SE (StataCorp, College Station TX, 
USA). Cox regression univariate analysis was performed for overall survival, and 
Kaplan-Meier method for survival curves. Multivariate statistical analysis was performed 
to test a correlation between the polymorphisms objet of study and the variables 
considered of interest. P-values less than 0.05 were considered as significant.  
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n.r. 
4. RESULTS 
In this study we enrolled 333 patients (155 female and 178 male) with a median age of 
64,7 years (range 28-90). The mean overall survival calculated was 52 months (134 
patients still alive, 186 non alive). Staging for gastric cancer revealed 155 patients (46%) 
with early stage gastric cancer (stage I-II), 53 patients (16%) with stage III and 115 
patients (34%) with stage IV (Figure 1). Lymph node were free from metastasis in 100 
patients, and metastatic in 211 patients. Distant metastasis were present in 71 patients and 
absent in 261 patients.  
 
 
Patient’s stratification for genetic polymorphisms are summarized in Figure 2, Figure 3 
and Figure 4.  
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Figure 1. Cancer stage  
(n.r. = undetermined)  
Figure 2. CXCL12 stratification according to 
genotypes. (n.r.= undetected). 
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Survival analysis reported no statistically significant results (p-value > 0.05) in allelic, 
dominant and recessive, genetic models. 
Grading analysis reported no statistically significant results (p-value > 0.05) in allelic, 
dominant and recessive, genetic models. 
Venous infiltration analysis reported no statistically significant results (p-value > 0.05) in 
allelic, dominant and recessive, genetic models. 
Lymphatic infiltration reported no statistically significant results (p-value > 0.05) in 
allelic, dominant and recessive, genetic models. 
Lymph node invasion analysis reported no statistically significant results (p-value > 0.05) 
in allelic, dominant and recessive, genetic models for CXCL12 and CRCR4. Instead, a 
0
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CC CT
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AA AT TT n.r.
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Figure 3. CXCR4 stratification according to genotypes. 
Figure 4. IL8 stratification according to genotypes. 
 (n.r. = undetermined).  
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weak association (p-value = 0.049) between genotypes A/A and A/T of rs4073 of the 
gene encoding for IL8 and lymph node involvement was found in the dominant model.  
The logistic regression performed for lymph node invasion as dependent variable and TT 
polymorphism as independent variable revealed an odds ratio of 0.60, p-value of 0.50 and 
a 95% confidence interval of 0.363-0.999; suggesting an association of the TT allele with 
a decrease risk to develop lymph node metastasis of 40%. However, at multivariate 
analysis, TT polymorphism was not correlated with T (primary tumor of TNM 
classification), so rs4073 seems not to ameliorate the information given by the T of the 
TNM classification for lymph node invasion.   
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5. DISCUSSION 
Gastric cancer and early stage gastric cancer, even if surgically curable, maintains a small 
prevalence of tumor recurrence and, finally, death. There are increasing bodies of 
evidence that the best risk stratification for cancer recurrence comes from TNM 
classification associated with specific molecular prognostic factors. Recent studies have 
shown that interactions between tumor and stromal cells create a unique 
microenvironment, essential for tumor growth and metastasis [49]. Chemokines affect 
tumor development indirectly by influencing angiogenesis, tumor leukocyte interactions, 
as well as directly by influencing tumor transformation, survival and growth, invasion and 
metastasis [50]. Metastasis is a frequent cause of death in patients with gastric cancer and 
can often occur after surgery, with absent or minimal lymph node involvement and 
without intra-operative macroscopic signs of peritoneal carcinomatosis [43]. Even early 
stages are at risk: once tumor cells have spread through the mucosa infiltration level 3 
(m3) and to the submucosa, the probability of metastasis increases rapidly and the 
likelihood of prolonged disease-free survival diminishes [51]. Thus, it is of major 
importance to identify those patients with a high risk for metastatic disease. Apart from 
hematogenous invasion in organ metastasis, peritoneal carcinomatosis of gastric 
carcinoma may develop from direct cancer cell dissemination into the abdominal cavity. 
The expression of chemokine receptors by tumor cells can be an important factor with 
regard to tumor cell dissemination and organ-specific metastases [52-54]. 
The CXCL12-CXCR4 pathway has been reported to impact the progression of various 
malignancies by  regulating trafficking of normal and malignant cells [34]. CXCL12-
CXCR4 also indirectly promotes tumor metastasis by mediating proliferation and 
migration of tumor cells and enhancing tumor-associated angiogenesis. The activation of  
angiogenesis seems to be regulated by pro-inflammatory cytokines, tumor necrosis factor 
 (TNF) and interferon .  Moreover the angiogenic effect of  CXCL12, which is 
expressed in the lung and other sites of metastasis, is partly mediated through an 
induction of  Vascular Endothelial Growth Factor (VEGF), suggesting an additive and 
synergistic mechanism to amplify angiogenesis [42]. CXCR4 is the chemokine receptor 
most commonly expressed in tumors and it is the receptor of CXCL12. The angiogenetic 
role of CXC12-CXCR4 pathway is confirmed by the neutralizing effect on angiogenesis 
of antibodies against either CXCL12 or CXCR4. 
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IL8 is a strong inducer of angiogenesis and also acts as a potent chemoattractant and 
activator of neutrophils and is closely related to the tumorigenesis, adhesion, invasion and 
metastasis of cancer [55]. IL8 have been shown to be angiogenic upon interaction with 
the appropriate chemokine receptors expressed on endothelial cells. Although endothelial 
cells are characterized by a large degree of heterogeneity dependent upon tissue types, 
species and vessel caliber, and it is therefore difficult to predict which effect IL8 will be 
dominant. 
In our study CXCL12, CXCL4 and IL8 polymorphisms did not impact overall survival of 
patients who underwent surgery for curative intent. A multivariate analysis was 
performed to identify correlation between the polymorphisms and gastric cancer grading, 
venous or lymphatic infiltration and lymph nodes metastasis.  
As shown in other studies [56-59], we observed an increased risk of lymph node 
metastasis in patients expressing A/A and A/T of rs4073 in the promoter region of the 
gene encoding for IL8. Even if the support from previous literature, we did not observed 
the expected results: no independent prognostic factor was found.  
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6. STUDY LIMITS 
 
We started our work from the idea that cancer microenvironment may have influenced the 
survival of our gastric cancer patients, so we focused on poorly studied angiogenetic 
factors (CXCL12, CRCR4 and IL8).  
The first problem we encountered was the lack of follow up data. Our retrospective 
observational study enrolled patients since 1992 so it was virtually impossible to 
understand the real cause of death. This is the reason why we calculated overall survival 
and not specific survival.  
Another limit is that we didn’t study for SNPs control subjects yet, but this  is one of the 
next target.  
Patient’s population is not enough to support rs1801157, rs2228014, rs4073 as 
independent prognostic factors for gastric cancer and in particular early stage gastric 
cancer.  
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6. CONCLUSIONS 
 
In conclusion our preliminary results are not conclusive and further studies are needed to 
clarify the intriguing role of angiogenetic cytokines polymorphisms and their role in the 
guide of lymph node metastatization and distant metastatization.  
A prospective case-control study is the next postdoc research topic.  
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